Aardvark Therapeutics Inc Dossier - Source-backed chat

Aardvark Therapeutics Inc

AARDNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.00

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $5.27Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $115.3M

Enterprise Value $41.5M

Shares Outstanding 24M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Aardvark Therapeutics is a clinical-stage biopharmaceutical company that recently transitioned to the public markets (IPO in February 2025). The company's investment thesis has been severely disrupted by safety setbacks. Its lead asset, ARD-101 (an oral bitter taste receptor agonist targeting hyperphagia in Prader-Willi Syndrome), was placed on a full clinical hold by the FDA in May 2026. This followed a voluntary pause in February 2026 due to reversible cardiac QRS prolongation observed at high doses in a healthy volunteer study. Consequently, the company has paused its entire clinical pipeline, including the Phase 3 HERO trial and Phase 2 obesity trials for ARD-201. While Aardvark possesses a solid cash buffer of $91.2 million (funding operations into mid-2027) and is actively unblinding accumulated HERO/OLE data to find a path forward, the regulatory and clinical risks are exceptionally high. Investors should maintain a Hold stance until unblinded data and FDA discussions clarify if a safe therapeutic window exists.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets10 analysts · as of 18 Aug 2026

Low · most bearish analyst$3.00

Mean target$14.50

High · most bullish analyst$45.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.5020%

Unblinded data reveal that cardiac QRS prolongation is mechanism-based and overlaps with the therapeutic dose range, or the efficacy signal is insufficient to justify the safety risks. The FDA clinical hold becomes permanent, forcing Aardvark to terminate the ARD-101 and ARD-201 programs, leaving the company with no active clinical pipeline and trading near cash value.

Base CaseCentral scenario

$5.0055%

The unblinded data show moderate efficacy, but confirming a safe therapeutic window requires additional nonclinical, pharmacokinetic, or cardiac monitoring studies. The FDA hold is eventually resolved, but clinical development is delayed by 12–18 months, requiring Aardvark to raise additional capital or seek a strategic partner before reaching regulatory approval.

Bull CaseUpside scenario

$12.0025%

The unblinded data from the 68 randomized HERO patients show strong, statistically significant efficacy in reducing hyperphagia with no cardiac signals at therapeutic doses. The FDA agrees to lift the clinical hold with minor protocol modifications (e.g., enhanced ECG monitoring or slight dose adjustments), allowing the Phase 3 trial to resume quickly and preserving a path to NDA submission.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Novel, first-in-class mechanism of action targeting bitter taste receptors (TAS2Rs) to stimulate gut-brain satiety signaling.
Sufficient cash reserves of $91.2 million as of March 31, 2026, providing a runway into mid-2027 to navigate the clinical hold.
Orphan Drug and Rare Pediatric Disease designations for ARD-101 in Prader-Willi Syndrome provide regulatory incentives if development resumes.

Key Investment Risks

Full FDA clinical hold on the lead asset ARD-101 halts all clinical progress.
Reversible cardiac QRS prolongation observed at high doses raises concerns about the therapeutic window and mechanism-based toxicity.
Entire clinical pipeline is currently paused, eliminating near-term clinical milestones and delaying the HERO trial readout indefinitely.

Thesis Invalidation Triggers

Permanent FDA clinical hold or refusal to allow resumption of the HERO trial.
Unblinded HERO trial data showing a lack of therapeutic efficacy or unexpected serious adverse events at lower doses.
Rapid cash burn accelerating the runway depletion to before mid-2027.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.